key: cord-0982622-jpoj7qf0
authors: Pathania, Y S
title: Use of cyclosporine therapy in dermatology during COVID-19 pandemic
date: 2022-02-02
journal: Actas Dermosifiliogr
DOI: 10.1016/j.ad.2021.10.009
sha: 1a2663d9553ee097a01a079ce35f3029cdab0545
doc_id: 982622
cord_uid: jpoj7qf0

nan

Correspondence: E-mail: yashdeepsinghpathania@gmail.com coronavirus 2 (SARS-CoV-2) has engulfed more than 227 countries in the world with its menace since more than 20 months. Dermatologists are striving for clear evidences for the use of the immunosuppressive agents which form an important part of their treatment armamentarium. Generally, immunosuppressive use has been prohibited during COVID-19, hence, this has posed restrictions and difficulty on the part of dermatologist to treat patients with severe or flare of diseases. Therefore, robust research is underway to find a suitable immunosuppressive agent which would treat the disease flare and simultaneously, does not pose higher chances of contracting the SARS-CoV-2 infection or worsen COVID-19 patient condition. Cyclosporine has emerged out to be an agent which has shown a ray of hope in such crucial times. Apart from immunosuppressive and anti-inflammatory effect, it has potent antiviral activity by inhibiting SARS-CoV replication at very low and non-toxic doses. 1 Cyclosporine role has been speculated in severe COVID-19 patients by abating cytokine storm. and HIV in a study. 8 Azathioprine, cyclophosphamide and methotrexate do not possess antiviral activity unlike cyclosporine. However, mycophenolate mofetil (MMF) has also some amount of anti-viral activity besides immunosuppression. It interferes with the early stage of the viral replication, before the protein synthesis. 9 In a study by C. Fotiadis et al. 10 , it was found that immunosuppression induced by MMF in maintaining graft function was median 2 days more than induced by cyclosporine. Therefore, MMF has a longer lasting immunosuppressive activity than cyclosporine and moreover, cyclosporine is better afforded than MMF. We have not encountered any COVID-19 infection in patients of acute flare of psoriasis, atopic dermatitis and Steven-Johnson syndrome who were administered cyclosporine therapy. A meta-analysis showed that cyclosporine had a beneficial effect on mortality for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) where rapid onset of treatment response as in Covid-19 is warranted. 11 Therefore, cyclosporine can be used in present scenario in patients presenting with dermatological emergencies like SJS, TEN, erythroderma secondary to psoriasis or atopic dermatitis. It can however, also be used in flares of diseases for a shorter period with better outcome.

Moreover, a recent comment supports the idea that cyclosporine might be the drug of choice during the COVID-19 pandemic for renal transplant recipient due to the in vitro evidence. 12 The results of randomized controlled trials on cyclosporine in COVID-19 are lacking and till then, its use in dermatology should be undertaken with guarded approach in the most suitable and essential cases along with strict monitoring of the blood levels to avert

Cyclosporin A inhibits the replication of diverse coronaviruses

Clinical features of cytokine storm syndrome

HLH across speciality collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)

Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection

Covid-19 infection in psoriasis patients treated with cyclosporin

Recovery of T -cell function in healthy dogs following cessation of oral cyclosporine administration

Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis--synergy study: a longitudinal observational study

Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans

Effects of mycophenolate mofetil vs cyclosporine administration on graft survival and function after islet allotransplantation in diabetic rats

Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis

COVID-19: implications for immunosuppression in kidney disease and transplantation